This phase I trial is testing escalating doses of a new oral therapy (RP4010) in lymphoma patients who have gotten worse or not responded to prior treatment.
This trial is treating patients with Lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients With Relapsed or Refractory Lymphomas
Rhizen Pharmaceuticals SA
This trial is evaluating the safety, pharmacokinetics and efficacy of RP4014, to be administered at escalating doses starting at 25 mg. This trial has a single group assignment.
Recruiting Hospitals Read More